CHAIMELEON aims to set up a structured repository for health imaging data to be openly reused in AI experimentation for cancer management. An EU-wide repository will be built as a distributed infrastructure in full compliance with legal and ethics regulations in the involved countries. It will build on partner´s experience (e.g. PRIMAGE repository for paediatric cancer and the Euro-BioImaging node for Valencia population, by HULAFE; the Radiomics Imaging Archive by Maastricht University; the national repository DRIM AI France, the Oncology imaging biobank by Pisa University). Clinical partners and external collaborators will populate the Repository with multimodality (MR, CT, PET/CT) imaging and related clinical data for historic and newly diagnosed lung, prostate, colon and rectal cancer patients. A multimodal analytical data engine will facilitate to interpret, extract and exploit the right information stored at the Repository. An ambitious development and implementation of AI-powered pipelines will enable advancement towards automating data deidentification, curation, annotation, integrity securing and images harmonisation, the latest being of the highest importance for enabling reproducibility of Radiomics when using large multiscanner/multicentre image datasets. The usability and performance of the Repository as a tool fostering AI experimentation will be validated, including a validation subphase by other world-class European AI developers, articulated via the organisation of Open Challenges to the AI Community. A set of selected AI tools will undergo early on-silico validation in observational (non-interventional) clinical studies coordinated by leading experts in Gustave Roussy (lung cancer), San Donato (breast), Sapienza (colon and rectal) and La Fe (prostate) hospitals. Their performance will be assessed, including external independent validation, on hallmark clinical decisions in response to some of the currently most important clinical end points in cancer.

The ongoing COVID-19 pandemic creates an unprecedented burden worldwide. Vaccine-induced immunity is the only promising solution. There is continued need for phase 2 & 3 vaccine trials to reach long-term, large-scale immunity of the entire European population. VACCELERATE will be the pan-European backbone accelerating phase 2 & 3 COVID-19 vaccine trials. The overall objective of VACCELERATE is to connect all European stakeholders involved in vaccine development to provide a pan-European platform for clinical trial design and conduct. VACCELERATE constitutes the rapid response single entry-point to stakeholders from public health authorities to vaccine developers, to address respective needs and kick-start specifically phase 2 & 3 vaccine trials. VACCELERATE conducts capacity mapping of clinical trial and laboratory sites to identify suitable sites for individual phase 2 & 3 vaccine trials. Capacity building via training will increase quality in sites across Europe. Volunteer registries facilitate patient recruitment. Access to laboratory sites and a standardised set of assays essential for clinical phase 2 & 3 trials is provided. A harmonised European approach to vaccine trials is enabled by aligning educational standards, coordination of laboratory support and providing standardised assays and trial protocols. Harmonised data collection, open data sharing and pooling of data for stronger analysis enables data standardisation. VACCELERATE offers solutions for characteristic vaccine development issues during pandemics by closing gaps in public health knowledge and improving knowledge transfer. VACCELERATE amalgamates the vast but scattered expertise across Europe into one network to deliver strategic scientific leadership and guidance on vaccine trials in Europe. Beyond the COVID-19 pandemic, it will be an established pandemic preparedness network, ready to face emerging future pandemics, as well as a pivot in Europe?s capacity to develop vaccines.

XpanDH is a CSA aimed at mobilizing and building capacity in individuals and organisations to create, adapt and explore purposeful use of interoperable digital health solutions based on a shared adoption of the European Electronic Health Records Exchange format (EEHRxF) across Europe. This pan-European effort will use a “network-of-networks” approach ensuring that digital health actors are motivated and supported by tailored guidance and real examples to help early adopters to advance to the concrete use of EEHRxF-embedded digital health solutions to add value to health and care and promote Personal and European Health Data Spaces. XpanDH pursues the main goal of maturing and accelerating a sustainable and scalable interoperability environment for digital health innovations based on the EEHRxF, around 5 Goals: 1) To develop robust technical specifications and resources for the EEHRxF building; 2) To establish the X-Bundle Readiness model; 3) To verify the usefulness of the X-Bundle in real-world with a set of early adopters grouped under selected adoption domains; 4) To mature a pan-European digital health ecosystem of solution providers and end-users, 5) To develop a framework for sustainable ecosystem. The consortium will thrive on past and ongoing eHealth interoperability projects and services, and particularly on the X-eHealth and DigitalHealthEurope projects recommendations, through digital health data activism and strong patient engagement. It brings together 26 Digital Health Actors under a co-creation and co-implementation concept, supported by a Policy Board (linking to Governments and the eHealth Network). To expand its impact, 10 XpandDH networks of hundreds of health stakeholders will be nurtured to form a vibrant pan-European (Digital) Health space converging on common, usable, and reliable tools for real interoperable services that adoption of the EEHRxF and enhance healthcare cooperation for better health towards a European Health Union.